A Dark Vector Cognition product

Thermo Fisher Scientific 10-Q 2026-09-26

TMO · CIK 97745 · Form 10-Q · Period ended September 26, 2026 · Filed October 30, 2026

Revenue rose 9.1% to $12.1 billion. Operating margin was 18.6%, against 17.5% a year earlier. Net income was $1.72 billion.

8 sections, 222K characters. Original on sec.gov · ·

Risk FactorsBusiness

Key numbers
MeasureQuarter ended Sep 26, 2026Quarter ended Sep 27, 2025Change
Revenue$12.1B$11.1B+9.1%
Operating income$2.26B$1.94B+16.6%
Net income$1.72B$1.62B+6.5%
Diluted EPS$4.64$4.27+8.7%
Cash and equivalents$5.46Bn/an/a
Operating margin*18.6%17.5%+1.2 pts

From the XBRL facts tagged to this filing; both columns are as reported in this filing. * Computed by filings.tools: free cash flow is operating cash flow less capital spending; operating margin is operating income over revenue.

The 66 tables in this filing as one CSV, figures in aligned columns. For subscribers: paste your API key. One API call. Plans from $19 a month, see pricing.

Cover and table of contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended September 26, 2026 or

☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Commission File Number 1-8002

THERMO FISHER SCIENTIFIC INC.

(Exact name of Registrant as specified in its charter)

Delaware04-2209186
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)

168 Third Avenue

Waltham, Massachusetts 02451

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (781) 622-1000

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $1.00 par valueTMONew York Stock Exchange
1.450% Notes due 2027TMO 27New York Stock Exchange
1.750% Notes due 2027TMO 27BNew York Stock Exchange
Floating Rate Notes due 2027TMO 27DNew York Stock Exchange
0.500% Notes due 2028TMO 28ANew York Stock Exchange
1.375% Notes due 2028TMO 28New York Stock Exchange
1.950% Notes due 2029TMO 29New York Stock Exchange
0.875% Notes due 2031TMO 31New York Stock Exchange
2.375% Notes due 2032TMO 32New York Stock Exchange
3.650% Notes due 2034TMO 34New York Stock Exchange
3.628% Notes due 2035TMO 35ANew York Stock Exchange
2.875% Notes due 2037TMO 37New York Stock Exchange
1.500% Notes due 2039TMO 39New York Stock Exchange
1.875% Notes due 2049TMO 49New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of September 26, 2026, the Registrant had 370,515,868 shares of Common Stock outstanding.

THERMO FISHER SCIENTIFIC INC.

QUARTERLY REPORT ON FORM 10-Q

FOR THE QUARTER ENDED SEPTEMBER 26, 2026

TABLE OF CONTENTS
Page
PART I - FINANCIAL INFORMATION
Item 1.Financial Statements (Unaudited)3
Condensed Consolidated Balance Sheets3
Condensed Consolidated Statements of Income4
Condensed Consolidated Statements of Comprehensive Income5
Condensed Consolidated Statements of Cash Flows6
Condensed Consolidated Statements of Redeemable Noncontrolling Interest and Equity7
Notes to Condensed Consolidated Financial Statements9
Note 1. Nature of Operations and Summary of Significant Accounting Policies9
Note 2. Supplemental Balance Sheet Information10
Note 3. Debt and Other Financing Arrangements11
Note 4. Fair Value Measurements14
Note 5. Commitments and Contingencies16
Note 6. Supplemental Income Statement Information17
Note 7. Income Taxes20
Note 8. Comprehensive Income/(Loss) and Shareholders' Equity21
Note 9. Supplemental Cash Flow Information21
Note 10. Derivatives22
Note 11. Business Segment Information24
Note 12. Acquisitions and Divestitures28
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations30
Item 3.Quantitative and Qualitative Disclosures About Market Risk40
Item 4.Controls and Procedures40
PART II - OTHER INFORMATION
Item 1.Legal Proceedings40
Item 1A.Risk Factors40
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds40
Item 5.Other Information41
Item 6.Exhibits41

THERMO FISHER SCIENTIFIC INC.

PART I FINANCIAL INFORMATION

Item 1. Financial Statements

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

September 26,December 31,
(In millions except share and per share amounts)20262025
Assets
Current assets:
Cash and cash equivalents$5,461$9,852
Short-term investments600253
Accounts receivable, less allowances of $135 and $1479,6258,900
Inventories5,6435,425
Contract assets, net1,6911,666
Other current assets2,5952,612
Total current assets25,61528,707
Property, plant and equipment, net10,57710,565
Acquisition-related intangible assets, net18,07715,838
Other assets5,7015,871
Goodwill54,26349,362
Total assets$114,233$110,343
Liabilities, redeemable noncontrolling interest and equity
Current liabilities:
Short-term obligations and current maturities of long-term obligations$2,262$3,533
Accounts payable3,0873,622
Accrued payroll and employee benefits2,0691,995
Contract liabilities2,9412,710
Other accrued expenses3,8113,329
Total current liabilities14,17015,189
Deferred income taxes1,4731,493
Other long-term liabilities4,5864,273
Long-term obligations39,10835,852
Redeemable noncontrolling interest128122
Equity:
Thermo Fisher Scientific Inc. shareholders’ equity:
Preferred stock, $100 par value, 50,000 shares authorized; none issued——
Common stock, $1 par value, 1,200,000,000 shares authorized; 446,511,736 and 445,160,301 shares issued447445
Capital in excess of par value19,24718,563
Retained earnings63,74059,156
Treasury stock at cost, 75,995,868 and 68,938,831 shares(26,408)(22,309)
Accumulated other comprehensive income/(loss)(2,264)(2,448)
Total Thermo Fisher Scientific Inc. shareholders’ equity54,76153,407
Noncontrolling interests67
Total equity54,76753,415
Total liabilities, redeemable noncontrolling interest and equity$114,233$110,343

The accompanying notes are an integral part of these condensed consolidated financial statements.

THERMO FISHER SCIENTIFIC INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)

Three months endedNine months ended
September 26,September 27,September 26,September 27,
(In millions except per share amounts)2026202520262025
Revenues
Product revenues$6,753$6,489$19,852$18,719
Service revenues5,3844,63315,28313,623
Total revenues12,13711,12235,13632,341
Costs and operating expenses:
Cost of product revenues3,3383,31910,0619,683
Cost of service revenues3,6683,22010,6339,431
Selling, general and administrative expenses2,3212,1626,8356,380
Research and development expenses3483461,0481,041
Restructuring and other costs199135346316
Total costs and operating expenses9,8749,18228,92326,850
Operating income2,2631,9416,2135,491
Interest income252234693735
Interest expense(417)(347)(1,172)(1,054)
Other income/(expense)(10)(2)13(18)
Income before income taxes2,0881,8265,7465,155
Benefit from/(provision for) income taxes(352)(207)(590)(394)
Equity in earnings/(losses) of unconsolidated entities(9)2(32)(9)
Net income1,7271,6215,1244,751
Less: net income/(loss) attributable to noncontrolling interests and redeemable noncontrolling interest651611
Net income attributable to Thermo Fisher Scientific Inc.$1,721$1,616$5,108$4,740
Earnings per share attributable to Thermo Fisher Scientific Inc.
Basic$4.65$4.28$13.77$12.55
Diluted$4.64$4.27$13.75$12.53
Weighted average shares

Showing the first 8K of 149K characters. Open the full section

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This Management’s Discussion and Analysis of Financial Condition and Results of Operations contains “forward-looking statements”, within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable securities laws. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties, and are often identified by words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “may,” “will,” “should,” or similar expressions or words with similar meanings. Any statements contained herein that are not statements of historical fact should be considered forward-looking statements.

Forward-looking statements in this Management’s Discussion and Analysis of Financial Condition and Results of Operations include, among others, statements regarding:

  • financial expectations**, including projections of revenues, expenses, margins, earnings, cash flows, liquidity, capital allocation plans, and tax matters;

  • operational matters**, including business strategies, productivity initiatives, restructuring activities, cost-reduction programs, and new product or service developments;

  • market and competitive conditions**, including customer demand trends, industry dynamics, pricing, and competitive positioning;

  • strategic actions**, including planned acquisitions, divestitures, investments, and partnerships;

  • legal, regulatory, macroeconomic, geopolitical, public health, supply chain, technology, and cybersecurity developments** and their potential impacts on the company; and

  • the timing and outcomes of any of the foregoing.

Each forward-looking statement contained in this Management’s Discussion and Analysis of Financial Condition and Results of Operations is inherently uncertain and involves significant risks, assumptions, and factors that could cause actual results to differ materially from those expressed or implied. Important risks and uncertainties that could cause such differences are detailed under the caption “Risk Factors” in the company’s Annual Report on Form 10-K for the year ended December 31, 2025, which is on file with the Securities and Exchange Commission (SEC).

Forward-looking statements in this Management’s Discussion and Analysis of Financial Condition and Results of Operations speak only as of the dates on which they are made. While the company may elect to update forward-looking statements in the future, it specifically disclaims any obligation to do so, in the event of new information, future developments, or otherwise, except as required by law.

The company refers to various amounts or measures not prepared in accordance with generally accepted accounting principles (non-GAAP measures). These non-GAAP measures are further described and reconciled to their most directly comparable amount or measure under the section “Non-GAAP Measures” later in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

Certain amounts and percentages reported within this Quarterly Report on Form 10-Q are presented and calculated based on underlying unrounded amounts. As a result, the sum of components may not equal corresponding totals due to rounding.

Overview

Thermo Fisher Scientific Inc. enables customers to make the world healthier, cleaner and safer by helping them accelerate life sciences research, solve complex analytical challenges, increase laboratory productivity, and improve patient health through diagnostics and the development and manufacture of life-changing therapies. Markets served include pharmaceutical and biotech, academic and government, industrial and applied, as well as healthcare and diagnostics. The company’s operations fall into four segments (Note 11): Life Sciences Solutions; Analytical Instruments; Specialty Diagnostics; and Laboratory Products and Biopharma Services.

THERMO FISHER SCIENTIFIC INC.

Consolidated Results

Three months endedNine months ended
September 26,September 27,September 26,September 27,
(Dollars in millions except per share amounts)20262025Change20262025Change
Revenues$12,137$11,1229%$35,136$32,3419%
GAAP operating income2,2631,94117%6,2135,49113%
GAAP operating income margin18.6%17.4%1.2pt17.7%17.0%0.7pt
Adjusted operating income (non-GAAP measure)2,9682,58715%8,1027,23112%
Adjusted operating income margin (non-GAAP measure)24.5%23.3%1.2pt23.1%22.4%0.7pt
GAAP diluted earnings per share attributable to Thermo Fisher Scientific Inc.4.644.279%13.7512.5310%
Adjusted earnings per share (non-GAAP measure)6.685.7915%18.1516.3011%

Organic Revenue Growth

Three months endedNine months ended
September 26, 2026September 26, 2026
Revenue growth9%9%
Impact of acquisitions/divestitures3%4%
Impact of currency translation0%1%
Organic revenue growth (non-GAAP measure)6%4%

During the third quarter of 2026, customer activity remained strong across our end markets. Revenue growth was very strong in the pharma and biotech market, as underlying market conditions continued to strengthen. Revenues in the academic and government market were flat. Revenue in the industrial and applied market was very strong, driven by customer demand for our innovative high-end instruments. Revenue to customers in the diagnostics and healthcare market also grew slightly. During the third quarter of 2026, sales increased across all major geographies. Revenue growth was strong in North America and Europe and very strong in Asia-Pacific, including China. Contributions to organic revenue during the third quarter of 2026 were led by the Laboratory Products and Biopharma Services segment and the Analytical Instruments segment.

During the first nine months of 2026, revenue growth in the pharma and biotech market was strong, with performance driven by strengthening underlying market conditions. Revenues in the academic and government market were flat. Revenues to customers in the industrial and applied market were also strong, driven by customer demand for our innovative high-end instruments. Revenues in the diagnostics and healthcare market grew slightly. During the first nine months of 2026, sales grew in North America. Revenue growth in Asia-Pacific, including China, and Europe was strong. Contributions to organic revenue during the first nine months of 2026 were led by the Laboratory Products and Biopharma Services segment.

The company continues to execute its proven growth strategy which consists of three pillars:

  • High-impact innovation;

  • Our trusted partner status with customers; and

  • Our unparalleled commercial engine.

GAAP operating income margin and adjusted operating income margin increased in the third quarter of 2026 due primarily to very strong productivity improvements, including tariff refunds realized, offset in part by strategic investments. GAAP operating income margin in the third quarter of 2026 also benefited from the recognition of net credits for changes in contingent consideration that did not occur in 2025, a gain on the sale of the microbiology business (Note 12), and lower levels of restructuring and other charges incurred for headcount reductions and consolidation of facilities when compared to the third quarter of 2025 (Note 6); however, this was largely offset by a held-for-sale loss (Note 12).

THERMO FISHER SCIENTIFIC INC.

GAAP operating income margin and adjusted operating income margin increased in the first nine months of 2026 due primarily to very strong productivity improvements, offset in part by unfavorable business mix and strategic investments. GAAP operating income margin also benefitted from lower levels of restructuring and other charges incurred for headcount reductions and consolidation of facilities (Note 6), largely offset by a held-for-sale loss (Note 12).

The company’s references to strategic investments generally refer to targeted spending for enhancing commercial capabilities, including expansion of geographic sales reach and e-commerce platforms, marketing initiatives, expanded service and operational infrastructure, research and development projects and other expenditures to enhance the customer experience, as well as incentive compensation and recognition for employees. The company’s references throughout this discussion to productivity improvements generally refer to the impact of its Practical Process Improvement (PPI) Business System to address inflation, drive cost efficiencies, improve profitability and, in 2026, the impact of tariff refunds realized. The benefits of PPI include optimized price realization, reduced costs resulting from implementing continuous improvement methodologies, global sourcing initiatives, a lower cost structure following restructuring actions including headcount reductions and consolidation of facilities, and low cost region manufacturing.

Notable Recent Acquisitions and Divestiture

On March 24, 2026, the company acquired, within the Laboratory Products and Biopharma Services segment, Clario Holdings, Inc., a U.S.-based leading provider of endpoint data solutions for clinical trials. The acquisition expands the segment’s portfolio with the addition of highly complementary clinical research offerings, enabling customers to gain critical insights from clinical data to improve decision-making, accelerate innovation and drive greater productivity.

On September 1, 2025, the company acquired, within the Life Sciences Solutions segment, our filtration and separation business, a leading provider of purification and filtration technologies used in the production of biologics as well as in medical technologies and industrial applications, from Solventum Corporation. The business strengthens the segment’s bioproduction offerings with advanced filtration technologies that improve quality and efficiency across upstream and downstream workflows. In addition, its industrial filtration and membrane solutions will expand our reach into industries including battery, semiconductor and medical device manufacturing.

On August 12, 2026, the company sold its microbiology business to Astorg. The business was part of the Specialty Diagnostics segment.

Segment Results

The company’s management evaluates segment operating performance using operating income before certain charges/credits as defined in Note 11 to the Consolidated Financial Statements of the company’s Annual Report on Form 10-K for 2025. Accordingly, the following segment data are reported on this basis.

Three months endedNine months ended
(Dollars in millions)September 26, 2026September 27, 2025September 26, 2026September 27, 2025
Revenues
Life Sciences Solutions$2,719$2,588$8,170$7,428
Analytical Instruments2,0021,8935,5645,339
Specialty Diagnostics1,0981,1743,4453,456
Laboratory Products and Biopharma Services6,8635,97019,59217,605
Eliminations(546)(503)(1,635)(1,487)
Consolidated revenues$12,137$11,122$35,136$32,341

THERMO FISHER SCIENTIFIC INC.

Life Sciences Solutions

Three months endedOrganic (non-GAAP measure)
(Dollars in millions)September 26, 2026September 27, 2025Total ChangeAcquisitions/ DivestituresCurrency Translation
Revenues$2,719$2,5885%4%0%1%
Segment income1,0229686%
Segment income margin37.6%37.4%0.2pt

The increase in organic revenues in the third quarter of 2026 was primarily driven by the bioproduction business. On a reported basis, the bioproduction business grew $79 million, which contributed 3 percentage points of reported growth in the segment, driven by higher demand from pharma and biotech customers, as well as the impact from the 2025 acquisition of the filtration and separation business. The increase in segment income margin resulted primarily from exceptionally strong productivity improvements, offset in part by unfavorable business mix, and the impact from the acquisition of the filtration and separation business.

Nine months endedOrganic (non-GAAP measure)
(Dollars in millions)September 26, 2026September 27, 2025Total ChangeAcquisitions/ DivestituresCurrency Translation
Revenues$8,170$7,42810%7%1%2%
Segment income3,0172,72211%
Segment income margin36.9%36.6%0.3pt

The increase in organic revenues in the first nine months of 2026 was driven by the bioproduction business. On a reported basis, the bioproduction business grew $496 million, driven by higher demand from pharma and biotech customers, as well as the impact from the 2025 acquisition of the filtration and separation business. The increase in segment income margin resulted primarily from exceptionally strong productivity improvements, partially offset by the impact from the filtration and separation business acquisition, and unfavorable business mix.

Analytical Instruments

Three months endedOrganic (non-GAAP measure)
(Dollars in millions)September 26, 2026September 27, 2025Total ChangeAcquisitions/ DivestituresCurrency Translation
Revenues$2,002$1,8936%0%0%6%
Segment income53842925%
Segment income margin26.9%22.6%4.3pt

The increase in organic revenues in the third quarter of 2026 was driven by growth in the electron microscopy and chromatography and mass spectrometry businesses. On a reported basis, the electron microscopy and chromatography and mass spectrometry businesses increased $94 million and $18 million, respectively, which contributed 5 percentage points and 1 percentage point of reported growth in the segment, respectively. The increase in segment income margin was driven by very strong productivity improvements, favorable volume leverage and business mix, offset in part by strategic investments.

THERMO FISHER SCIENTIFIC INC.

Nine months endedOrganic (non-GAAP measure)
(Dollars in millions)September 26, 2026September 27, 2025Total ChangeAcquisitions/ DivestituresCurrency Translation
Revenues$5,564$5,3394%0%1%3%
Segment income1,3171,15314%
Segment income margin23.7%21.6%2.1pt

The increase in organic revenues in the first nine months of 2026 was primarily due to growth in the electron microscopy and chromatography and mass spectrometry businesses. On a reported basis, the electron microscopy and chromatography and mass spectrometry businesses grew $123 million and $81 million, respectively, which contributed 2 percentage points each of reported growth in the segment. The increase in segment income margin was primarily driven by strong productivity improvements.

Specialty Diagnostics

Three months endedOrganic (non-GAAP measure)
(Dollars in millions)September 26, 2026September 27, 2025Total ChangeAcquisitions/ DivestituresCurrency Translation
Revenues$1,098$1,174(6)%(6)%0%0%
Segment income3413216%
Segment income margin31.0%27.4%3.6pt

Organic revenues were flat in the third quarter of 2026. On a reported basis, segment revenues declined, primarily driven by the impact of the microbiology business divestiture. The increase in segment income margin was driven by exceptionally strong productivity improvements.

Nine months endedOrganic (non-GAAP measure)
(Dollars in millions)September 26, 2026September 27, 2025Total ChangeAcquisitions/ DivestituresCurrency Translation
Revenues$3,445$3,4560%(2)%1%1%
Segment income9879326%
Segment income margin28.7%27.0%1.7pt

Organic revenues in the first nine months of 2026 increased, led by the transplant diagnostics and the immunodiagnostics businesses. On a reported basis, the impact of the microbiology business divestiture was offset by modest growth across the segment’s other businesses. The increase in segment income margin was primarily due to strong productivity improvements.

Laboratory Products and Biopharma Services

Three months endedOrganic (non-GAAP measure)
(Dollars in millions)September 26, 2026September 27, 2025Total ChangeAcquisitions/ DivestituresCurrency Translation
Revenues$6,863$5,97015%6%0%10%
Segment income1,06786823%
Segment income margin15.5%14.5%1.0pt

The increase in organic revenues in the third quarter of 2026 was primarily due to growth in the pharma services business, research and safety market channel, and the clinical research business. On a reported basis, the clinical research business grew $425 million, which contributed 7 percentage points of reported growth in the segment, primarily driven by the impact of the Clario acquisition. The pharma services business and research and safety market channel grew $306 million and $169 million, respectively, which contributed 5 percentage points and 3 percentage points, respectively, of reported growth in the segment. The increase in segment income margin was primarily due to strong productivity improvements, the impact of the Clario acquisition, partially offset by strategic investments.

THERMO FISHER SCIENTIFIC INC.

Nine months endedOrganic (non-GAAP measure)
(Dollars in millions)September 26, 2026September 27, 2025Total ChangeAcquisitions/ DivestituresCurrency Translation
Revenues$19,592$17,60511%4%1%6%
Segment income2,7812,42515%
Segment income margin14.2%13.8%0.4pt

The increase in organic revenues in the first nine months of 2026 was primarily due to growth in the clinical research business, research and safety market channel, and pharma services business. On a reported basis, the clinical research business grew approximately $1.05 billion, which contributed 6 percentage points of reported growth in the segment, primarily driven by the impact of the Clario acquisition. The pharma services business and research and safety market channel grew $539 million and $422 million, respectively, which contributed 3 percentage points and 2 percentage points, respectively, of reported growth in the segment. The increase in segment income margin was primarily due to strong productivity improvements, offset in part by strategic investments.

Non-operating Items

Three months endedNine months ended
September 26,September 27,September 26,September 27,
(Dollars and shares in millions)2026202520262025
Net interest expense$165$113$479$319
GAAP other income/(expense)(10)(2)13(18)
Adjusted other income/(expense) (non-GAAP measure)5(7)(3)(19)
GAAP tax rate16.9%11.3%10.3%7.6%
Adjusted tax rate (non-GAAP measure)11.6%11.0%11.3%10.4%
Weighted average diluted shares371378372378

Net interest expense (interest expense less interest income) in the third quarter and first nine months of 2026 increased, due primarily to the increase in debt for general corporate purposes and the company’s capital deployment initiatives, which included financing stock buybacks, paying dividends, and acquiring Clario (Note 12). In the third quarter and first nine months of 2026, the company’s net interest expense was reduced by $102 million and $296 million, respectively, as a result of its interest rate swap and cross-currency interest rate swap arrangements. In the third quarter and first nine months of 2025, the company’s net interest expense was reduced by $66 million and $199 million, respectively, as a result of its interest rate swap and cross-currency interest rate swap arrangements (Note 10).

GAAP other income/(expense) and adjusted other income/(expense) include currency transaction gains/losses on non-operating monetary assets and liabilities, and net periodic pension benefit cost/income, excluding the service cost component. GAAP other income/(expense) in the third quarter and first nine months of 2026 also includes $(13) million and $10 million, respectively, of net gains/(losses) on investments. GAAP other income/(expense) in the first nine months of 2026 also includes $6 million of business interruption recoveries. GAAP other income/(expense) in the third quarter and first nine months of 2025 also includes $7 million and $9 million, respectively, of net gains on investments, and $2 million and $8 million, respectively, of settlement charges for pension plans.

The company’s GAAP and adjusted tax rates in the third quarter of 2026 were impacted by a $161 million deferred tax benefit resulting from the recognition of tax attributes related to a domestication transaction. The company’s GAAP tax rate in the third quarter of 2026 was also impacted by a $171 million tax expense related to the tax gain associated with the sale of the microbiology business that was completed during the quarter. The company’s GAAP and adjusted tax rates in the first nine months of 2026 were impacted by $175 million of deferred tax benefits resulting from the recognition of tax attributes related to domestication transactions and a deferred tax benefit of $148 million in jurisdictions where the deferred tax assets are now expected to be realized due to forecasted income. The company’s GAAP and adjusted tax rates in the third quarter of 2025 were impacted by an $86 million tax benefit from tax return reassessments. The company’s GAAP tax rate in the third quarter of 2025 was also impacted by tax legislation enacted during the quarter. The company’s GAAP and adjusted tax rates in the first nine months of 2025 were impacted by a $125 million deferred tax benefit resulting from the recognition of a tax

THERMO FISHER SCIENTIFIC INC.

attribute related to a domestication transaction, a deferred tax benefit of $153 million related to capital losses generated as part of intra-entity transactions, and a $93 million benefit in jurisdictions where the deferred tax assets are now expected to be realized due to forecasted income (Note 7).

The effective tax rates in both 2026 and 2025 were also affected by relatively significant earnings in lower tax jurisdictions. Due primarily to the non-deductibility of intangible asset amortization for tax purposes, the company’s cash payments for income taxes are higher than its income tax expense for financial reporting purposes and are expected to total approximately $1.5 billion in 2026.

The company expects its GAAP effective tax rate in 2026 will be between 9% and 11% based on currently forecasted rates of profitability in the countries in which the company conducts business and generates foreign tax credits. The effective tax rate can vary significantly from period to period as a result of discrete income tax factors and events. The company expects its adjusted tax rate will be approximately 11.5% in 2026.

The company has operations and a taxable presence in approximately 70 countries outside the U.S. Some of these countries have lower tax rates than the U.S. The company’s ability to obtain a benefit from lower tax rates outside the U.S. is dependent on its relative levels of income in countries outside the U.S. and on the statutory tax rates in those countries. Based on the dispersion of the company’s non-U.S. income tax provision among many countries, the company believes that a change in the statutory tax rate in any individual country is not likely to materially affect the company’s income tax provision or net income.

Weighted average diluted shares decreased in 2026 compared to 2025, primarily due to share repurchases, net of option dilution.

Liquidity and Capital Resources

The company’s proven growth strategy has enabled it to generate free cash flow as well as access the capital markets. The company deploys its capital primarily via mergers and acquisitions and secondarily via share buybacks and dividends.

(In millions)September 26, 2026December 31, 2025
Cash and cash equivalents$5,461$9,852
Short-term investments600253
Total debt41,37039,384

Approximately half of the company’s cash balances and cash flows from operations are generated outside the U.S. The company uses its non-U.S. cash for needs outside of the U.S., including acquisitions, capacity expansion, and repayment of third-party foreign debt by foreign subsidiaries. In addition, the company also transfers cash to the U.S. using non-taxable intercompany transactions, including loans and returns of capital, as well as dividends where the related U.S. dividend received deduction or foreign tax credit equals any tax cost arising from the dividends. As a result of using such means of transferring cash to the U.S., the company does not expect any material adverse liquidity effects from its significant non-U.S. cash balances for the foreseeable future.

The company believes that its existing cash and cash equivalents and its future cash flow from operations together with available borrowing capacity under its revolving credit agreement will be sufficient to meet the cash requirements of its existing businesses for the foreseeable future, including at least the next 24 months.

As of September 26, 2026, the company’s short-term obligations and current maturities of long-term obligations totaled $2.26 billion. The company has a revolving credit facility with a bank group that provides up to $5.00 billion of unsecured multi-currency revolving credit (Note 3). If the company borrows under this facility, it intends to leave undrawn an amount equivalent to outstanding commercial paper to provide a source of funds in the event that commercial paper markets are not available. As of September 26, 2026, no borrowings were outstanding under the company’s revolving credit facility.

THERMO FISHER SCIENTIFIC INC.

Nine months ended
(In millions)September 26, 2026September 27, 2025
Net cash provided by operating activities$5,867$4,361
Net cash used in investing activities(8,874)(4,938)
Net cash used in financing activities(1,541)(1,725)
Free cash flow (non-GAAP measure)4,6183,319

Operating Activities

During the first nine months of 2026, cash provided by net income was offset in part by investments in working capital. An increase in accounts receivable used cash of $0.54 billion. A decrease in accounts payable used cash of $0.43 billion. Cash payments for income taxes were $0.94 billion during the first nine months of 2026.

During the first nine months of 2025, cash provided by income was offset in part by investments in working capital. Changes in other assets and liabilities used cash of $1.21 billion primarily due to the timing of payments for compensation and income taxes. Cash payments for income taxes were $1.60 billion during the first nine months of 2025.

Investing Activities

During the first nine months of 2026, acquisitions used cash of $8.88 billion, and proceeds from the sale of the company’s microbiology business provided cash of $1.02 billion (Note 12). Purchases of property, plant and equipment for capacity and capability investments used cash of $1.26 billion.

During the first nine months of 2025, acquisitions used cash of $4.04 billion. The company’s investing activities also included $1.06 billion for the purchase of property, plant and equipment for capacity and capability investments.

The company expects that for all of 2026, expenditures for property, plant and equipment, net of disposals, will be between $1.9 billion and $2.0 billion.

Financing Activities

During the first nine months of 2026, issuance of debt provided $5.24 billion of cash. Repayment of debt used cash of $2.52 billion. The company’s financing activities also included the repurchase of $4.00 billion of the company’s common stock (6.9 million shares), and the payment of $0.51 billion in cash dividends. On November 6, 2025, the Board of Directors authorized the repurchase of up to $5.00 billion of the company’s common stock. All of the shares of common stock repurchased by the company during the first nine months of 2026 were under this program. At October 30, 2026, $1.00 billion was available for future repurchases of the company’s common stock under this authorization.

During the first nine months of 2025, issuance of debt and net commercial paper activity provided $3.34 billion of cash. Repayment of debt used cash of $1.63 billion. The company’s financing activities also included the repurchase of $3.00 billion of the company’s common stock (5.8 million shares), of which $0.04 billion settled in the fourth quarter of 2025, and the payment of $0.47 billion in cash dividends.

The company’s commitments for purchases of property, plant and equipment, contractual obligations and other commercial commitments, did not change materially subsequent to December 31, 2025, except in connection with the completion of the Clario acquisition, which occurred on March 24, 2026 (Note 12).

Non-GAAP Measures

In addition to the financial measures prepared in accordance with GAAP, we use certain non-GAAP financial measures such as organic revenue growth, which is reported revenue growth, excluding the impacts of revenues from acquired/divested businesses and the effects of currency translation. We report organic revenue growth because Thermo Fisher management believes that in order to understand the company’s short-term and long-term financial trends, investors may wish to consider the impact of acquisitions/divestitures and foreign currency translation on revenues. Thermo Fisher management uses organic revenue growth to forecast and evaluate the operational performance of the company as well as to compare revenues of current periods to prior periods.

We report adjusted operating income, adjusted operating income margin, adjusted other income/(expense), adjusted tax rate, and adjusted EPS. We believe that the use of these non-GAAP financial measures, in addition to

THERMO FISHER SCIENTIFIC INC.

GAAP financial measures, helps investors to gain a better understanding of our core operating results and future prospects, consistent with how management measures and forecasts the company’s core operating performance, especially when comparing such results to previous periods, forecasts, and to the performance of our competitors. Such measures are also used by management in their financial and operating decision-making and for compensation purposes. To calculate these measures we exclude, as applicable:

  • Certain transaction-related costs, including charges for the sale of inventories revalued at the date of acquisition, significant transaction-related third-party costs, changes in estimates of contingent acquisition-related consideration, and other costs associated with obtaining short-term financing commitments for pending/recent acquisitions. We exclude these costs because we do not believe they are indicative of our normal operating costs.

  • Costs/income associated with restructuring activities and large-scale abandonments of product lines, such as reducing overhead and consolidating facilities. We exclude these costs because we believe that the costs related to restructuring activities and large-scale abandonment of product lines are not indicative of our normal operating costs.

  • Equity in earnings/losses of unconsolidated entities; impairments of long-lived assets; and certain other gains and losses that are either isolated or cannot be expected to occur again with any predictability, including gains/losses on investments, the sale of businesses, product lines, and real estate, significant litigation-related matters, curtailments/settlements of pension plans, and the early retirement of debt. We exclude these items because they are outside of our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods.

  • The expense associated with the amortization of acquisition-related intangible assets because a significant portion of the purchase price for acquisitions may be allocated to intangible assets that have lives of up to 20 years. Exclusion of the amortization expense allows comparisons of operating results that are consistent over time for both our newly acquired and long-held businesses and with both acquisitive and non-acquisitive peer companies.

  • The noncontrolling interest and tax impacts of the above items and the impact of significant tax audits or events (such as changes in deferred taxes from enacted tax rate/law changes), the latter of which we exclude because they are outside of our normal operations and difficult to forecast accurately for future periods.

We report free cash flow, which is operating cash flow less net capital expenditures, to provide a view of the continuing operations’ ability to generate cash for use in acquisitions and other investing and financing activities. The company also uses this measure as an indication of the strength of the company. Free cash flow is not a measure of cash available for discretionary expenditures since we have certain non-discretionary obligations such as debt service that are not deducted from the measure.

The non-GAAP financial measures of the company’s results of operations and cash flows included in this Form 10-Q are not meant to be considered superior to or a substitute for the company’s results of operations prepared in accordance with GAAP. Reconciliations of such non-GAAP financial measures to the most directly comparable GAAP financial measures are set forth within the “Consolidated Results” and “Segment Results” sections and below.

Three months endedNine months ended
September 26,September 27,September 26,September 27,
(Dollars in millions except per share amounts)2026202520262025
Reconciliation of adjusted operating income
GAAP operating income$2,263$1,941$6,213$5,491
Cost of revenues adjustments (a)9105131
Selling, general and administrative expenses adjustments (b)(20)665999
Restructuring and other costs (c)199135346316
Amortization of acquisition-related intangible assets5194351,4331,294
Adjusted operating income (non-GAAP measure)$2,968$2,587$8,102$7,231

THERMO FISHER SCIENTIFIC INC.

Three months endedNine months ended
September 26,September 27,September 26,September 27,
(Dollars in millions except per share amounts)2026202520262025
Reconciliation of adjusted operating income margin
GAAP operating income margin18.6%17.4%17.7%17.0%
Cost of revenues adjustments (a)0.1%0.1%0.1%0.1%
Selling, general and administrative expenses adjustments (b)(0.2)%0.6%0.2%0.3%
Restructuring and other costs (c)1.6%1.2%1.0%1.0%
Amortization of acquisition-related intangible assets4.3%3.9%4.1%4.0%
Adjusted operating income margin (non-GAAP measure)24.5%23.3%23.1%22.4%
Reconciliation of adjusted other income/(expense)
GAAP other income/(expense)$(10)$(2)$13$(18)
Adjustments (d)14(5)(15)(1)
Adjusted other income/(expense) (non-GAAP measure)$5$(7)$(3)$(19)
Reconciliation of adjusted tax rate
GAAP tax rate16.9%11.3%10.3%7.6%
Adjustments (e)(5.3)%(0.3)%1.0%2.7%
Adjusted tax rate (non-GAAP measure)11.6%11.0%11.3%10.4%
Reconciliation of adjusted earnings per share
GAAP diluted earnings per share (EPS) attributable to Thermo Fisher Scientific Inc.$4.64$4.27$13.75$12.53
Cost of revenues adjustments (a)0.020.030.140.08
Selling, general and administrative expenses adjustments (b)(0.06)0.170.160.26
Restructuring and other costs (c)0.540.360.930.83
Amortization of acquisition-related intangible assets1.401.153.863.42
Other income/expense adjustments (d)0.04(0.01)(0.04)0.00
Income taxes adjustments (e)0.07(0.17)(0.72)(0.85)
Equity in earnings/losses of unconsolidated entities0.02(0.01)0.090.02
Noncontrolling interests adjustments (f)—0.00—0.00
Adjusted EPS (non-GAAP measure)$6.68$5.79$18.15$16.30
Reconciliation of free cash flow
GAAP net cash provided by operating activities$2,551$2,239$5,867$4,361
Purchases of property, plant and equipment(437)(404)(1,263)(1,060)
Proceeds from sale of property, plant and equipment151417
Free cash flow (non-GAAP measure)$2,115$1,840$4,618$3,319

(a)Adjusted results exclude accelerated depreciation on manufacturing assets to be abandoned due to facility consolidations and charges/(credits) for the sale of inventory revalued at the date of acquisition. Adjusted results in 2026 also exclude $16 million of transaction-related costs.

(b)Adjusted results exclude certain third-party expenses, principally transaction/integration costs, charges/credits for changes in estimates of contingent acquisition consideration, accelerated depreciation on fixed assets to be abandoned due to facility consolidations, and charges for product liability litigation.

(c)Adjusted results exclude restructuring and other costs consisting principally of severance, impairments of long-lived assets, net charges/credits for pre-acquisition litigation and other matters, net gains/losses on the sale of real estate, and abandoned facility and other expenses of headcount reductions and real estate consolidations. Adjusted results in 2026 exclude $72 million of gain on the sale of a business and $244 million for a held-for-sale loss. Adjusted results in 2025 also exclude $51 million of charges for disposition of a consolidated joint venture.

THERMO FISHER SCIENTIFIC INC.

(d)Adjusted results exclude net gains/losses on investments and settlement charges for pension plans. Adjusted results in 2026 also exclude $6 million of business interruption recoveries.

(e)Adjusted results exclude incremental tax impacts for the reconciling items between GAAP and adjusted net income, incremental tax impacts as a result of tax rate/law changes, and the tax impacts from audit settlements.

(f)Adjusted results exclude the incremental impacts for the reconciling items between GAAP and adjusted net income attributable to noncontrolling interests.

Critical Accounting Policies and Estimates

Management’s Discussion and Analysis and Note 1 to the Consolidated Financial Statements of the company’s Annual Report on Form 10-K for 2025 describe the significant accounting estimates and policies used in preparation of the consolidated financial statements. There have been no significant changes in the company’s critical accounting policies during the first nine months of 2026.

Recent Accounting Pronouncements

A description of recently issued accounting standards is included under the heading “Recent Accounting Pronouncements” in Note 1.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

The company’s exposure to market risk from changes in interest rates and currency exchange rates has not changed materially from its exposure discussed in the company’s Annual Report on Form 10-K for the year ended December 31, 2025.

Item 4. Controls and Procedures

Management’s Evaluation of Disclosure Controls and Procedures

The company’s management, with the participation of the company’s chief executive officer and chief financial officer, has evaluated the effectiveness of the company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on such evaluation, the company’s chief executive officer and chief financial officer concluded that, as of the end of such period, the company’s disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

There have been no changes in the company’s internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) during the fiscal quarter ended September 26, 2026, that have materially affected or are reasonably likely to materially affect the company’s internal control over financial reporting.

PART II OTHER INFORMATION

Item 1. Legal Proceedings

There are various lawsuits and claims against the company involving product liability, intellectual property, employment and commercial issues. See Note 5 to our Condensed Consolidated Financial Statements under the heading “Commitments and Contingencies.”

Item 1A. Risk Factors

The risks that we believe are material to our investors are detailed under the caption “Risk Factors” in the company’s Annual Report on Form 10-K for the year ended December 31, 2025 (which is on file with the SEC).

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Issuer Purchases of Equity Securities

There was no share repurchase activity for the company's third quarter of 2026. On November 6, 2025, the Board of Directors authorized the repurchase of up to $5.00 billion of the company’s common stock. At September 26, 2026, $1.00 billion was available for future repurchases of the company’s common stock under this authorization.

THERMO FISHER SCIENTIFIC INC.

Item 5. Other Information

Director and Officer Trading Arrangements

During the three months ended September 26, 2026, no director or executive officer of the company adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

Item 6. Exhibits

Exhibit NumberDescription of Exhibit
31.1Certification of Chief Executive Officer required by Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2Certification of Chief Financial Officer required by Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1Certification of Chief Executive Officer required by Exchange Act Rules 13a-14(b) and 15d-14(b), as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**
32.2Certification of Chief Financial Officer required by Exchange Act Rules 13a-14(b) and 15d-14(b), as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**
101.INSXBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCHXBRL Taxonomy Extension Schema Document.
101.CALXBRL Taxonomy Calculation Linkbase Document.
101.DEFXBRL Taxonomy Definition Linkbase Document.
101.LABXBRL Taxonomy Label Linkbase Document.
101.PREXBRL Taxonomy Presentation Linkbase Document.
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
The Registrant agrees, pursuant to Item 601(b)(4)(iii)(A) of Regulation S-K, to furnish to the Commission, upon request, a copy of each instrument with respect to long-term debt of the Registrant or its consolidated subsidiaries.

** Certification is not deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section. Such certification is not deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act except to the extent that the registrant specifically incorporates it by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date:October 30, 2026THERMO FISHER SCIENTIFIC INC.
/s/ James R. Meyer
James R. Meyer
Senior Vice President and Chief Financial Officer
/s/ Joseph R. Holmes
Joseph R. Holmes
Vice President and Chief Accounting Officer